Luminex Cor (LMNX) 15.45 $LMNX
Varian Medical's ProBeam Proton Therapy Now in Denmark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:43PM CST
In addition to the ProBeam system, Varian Medical Systems Inc. (VAR) will provide the Denmark center with its ARIA information management software.
ABMD: 60.39 (+0.46), VAR: 92.65 (+0.03), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Cepheid Strong on Q4, Global Expansion; Currency Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 1:09PM CST
Cepheid (CPHD) reported adjusted breakeven earnings per share in the quarter, which compared favorably with the Zacks Consensus Estimate of a loss of 14 cents.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72), LMNX: 15.45 (+0.02)
Thoratec Beats Q4 Earnings and Revenues, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:45AM CST
Shares of Thoratec Corp. (THOR) rallied 4.37% ($1.59) to $38.00 after the company reported impressive fourth-quarter financial numbers.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), THOR: 40.01 (+0.54), LMNX: 15.45 (+0.02)
Luminex (LMNX) Downgraded From Buy to Hold
at The Street - Tue Feb 10, 11:20AM CST
Luminex (LMNX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
LMNX: 15.45 (+0.02)
Luminex (LMNX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 6:19AM CST
Luminex (LMNX) Enters Oversold Territory
LMNX: 15.45 (+0.02)
Fluidigm Q4 Loss Narrower Than Expected, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:10AM CST
Following the earnings announcement on Feb 5, shares of Fluidigm Corp (FLDM) rallied nearly 2.8% to open at $39.85 on Friday.
ABMD: 60.39 (+0.46), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Accuray's TomoTherapy Gains Traction in Latin America (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:00AM CST
Accuray Inc's (ARAY) TomoTherapy System recently started operating breast cancer patients at Fundacion de Cancer de Mama (FUCAM) in Mexico City
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ARAY: 8.00 (+0.24), LMNX: 15.45 (+0.02)
Mettler-Toledo Tops Earnings, Revenues on Margin Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:16AM CST
Mettler-Toledo International Inc. (MTD) reported an impressive fourth-quarter 2014 wherein adjusted EPS of $4.24 beat the Zacks Consensus Estimate by 9 cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), MTD: 307.00 (-0.13)
Accuray's TomoTherapy Gains Traction in Latin America - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:25PM CST
Accuray Inc's (ARAY) TomoTherapy System recently started operating breast cancer patients at Fundacion de Cancer de Mama (FUCAM) in Mexico City.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), ARAY: 8.00 (+0.24)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Luminex (LMNX): Strong Buy on Solid Q4 & Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 6:32PM CST
On Feb 4, 2015, Zacks Investment Research raised Luminex Corp (LMNX) to a Zacks Rank #1 (Strong Buy).
ABMD: 60.39 (+0.46), TMO: 127.61 (+0.78), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Edwards Lifesciences Tops Q4 Earnings, Sales; Alters View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:10AM CST
Edwards Lifesciences (EW) reported sales of $618 million, up 15.3% year over year. The top line also outshone the Zacks Consensus Estimate of $609 million.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), LMNX: 15.45 (+0.02)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
HEOP: 7.89 (+0.03), ENI: 16.20 (+0.24), MFSF: 22.86 (+0.05), LMNX: 15.45 (+0.02), MMSI: 17.27 (-0.16)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Why Luminex Corporation Shares Got Slashed
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:06PM CST
Source: Luminex Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Luminex...
LMNX: 15.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Luminex (LMNX) Q4 Earnings Top, Revenues Meet Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 8:30AM CST
Luminex Corporation (LMNX) reported fourth-quarter 2014 adjusted earnings per share (EPS) of 15 cents, which managed to beat the Zacks Consensus Estimate by 3 cents. However, adjusted EPS fell by a penny on a year-over-year basis
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex Gets Health Canada Approval for Genotyping Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 5:35PM CST
Developer and seller of proprietary biological testing technologies, Luminex Corp (LMNX), recently received Health Canada approval for its genotyping assay, xTAG CYP2D6 Kit v3.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex CF Ops up 71%
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:37PM CST
LMNX: 15.45 (+0.02)
Varian Medical's ProBeam Proton Therapy Now in Denmark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:43PM CST
In addition to the ProBeam system, Varian Medical Systems Inc. (VAR) will provide the Denmark center with its ARIA information management software.
ABMD: 60.39 (+0.46), VAR: 92.65 (+0.03), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Cepheid Strong on Q4, Global Expansion; Currency Woes Stay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 1:09PM CST
Cepheid (CPHD) reported adjusted breakeven earnings per share in the quarter, which compared favorably with the Zacks Consensus Estimate of a loss of 14 cents.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), CPHD: 59.62 (+0.72), LMNX: 15.45 (+0.02)
Thoratec Beats Q4 Earnings and Revenues, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:45AM CST
Shares of Thoratec Corp. (THOR) rallied 4.37% ($1.59) to $38.00 after the company reported impressive fourth-quarter financial numbers.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), THOR: 40.01 (+0.54), LMNX: 15.45 (+0.02)
Luminex (LMNX) Downgraded From Buy to Hold
at The Street - Tue Feb 10, 11:20AM CST
Luminex (LMNX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
LMNX: 15.45 (+0.02)
Luminex (LMNX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 6:19AM CST
Luminex (LMNX) Enters Oversold Territory
LMNX: 15.45 (+0.02)
Fluidigm Q4 Loss Narrower Than Expected, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:10AM CST
Following the earnings announcement on Feb 5, shares of Fluidigm Corp (FLDM) rallied nearly 2.8% to open at $39.85 on Friday.
ABMD: 60.39 (+0.46), FLDM: 37.93 (-0.47), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Accuray's TomoTherapy Gains Traction in Latin America (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:00AM CST
Accuray Inc's (ARAY) TomoTherapy System recently started operating breast cancer patients at Fundacion de Cancer de Mama (FUCAM) in Mexico City
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), ARAY: 8.00 (+0.24), LMNX: 15.45 (+0.02)
Mettler-Toledo Tops Earnings, Revenues on Margin Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:16AM CST
Mettler-Toledo International Inc. (MTD) reported an impressive fourth-quarter 2014 wherein adjusted EPS of $4.24 beat the Zacks Consensus Estimate by 9 cents
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), MTD: 307.00 (-0.13)
Accuray's TomoTherapy Gains Traction in Latin America - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:25PM CST
Accuray Inc's (ARAY) TomoTherapy System recently started operating breast cancer patients at Fundacion de Cancer de Mama (FUCAM) in Mexico City.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), ARAY: 8.00 (+0.24)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Luminex (LMNX): Strong Buy on Solid Q4 & Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 6:32PM CST
On Feb 4, 2015, Zacks Investment Research raised Luminex Corp (LMNX) to a Zacks Rank #1 (Strong Buy).
ABMD: 60.39 (+0.46), TMO: 127.61 (+0.78), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02)
Edwards Lifesciences Tops Q4 Earnings, Sales; Alters View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:10AM CST
Edwards Lifesciences (EW) reported sales of $618 million, up 15.3% year over year. The top line also outshone the Zacks Consensus Estimate of $609 million.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), EW: 134.23 (+1.89), LMNX: 15.45 (+0.02)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
HEOP: 7.89 (+0.03), ENI: 16.20 (+0.24), MFSF: 22.86 (+0.05), LMNX: 15.45 (+0.02), MMSI: 17.27 (-0.16)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), OPHT: 51.11 (+0.12), LMNX: 15.45 (+0.02), ENTA: 33.30 (-0.44), ORPN: 7.17 (+0.04), EVOK: 5.41 (-0.10), RCII: 30.49 (+0.92), SCYX: 9.48 (+0.07), SSYS: 67.16 (-0.34), AKBA: 9.32 (+0.51), VBLT: 14.11 (+0.24)
Why Luminex Corporation Shares Got Slashed
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 03, 2:06PM CST
Source: Luminex Corporation Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Luminex...
LMNX: 15.45 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Luminex (LMNX) Q4 Earnings Top, Revenues Meet Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 8:30AM CST
Luminex Corporation (LMNX) reported fourth-quarter 2014 adjusted earnings per share (EPS) of 15 cents, which managed to beat the Zacks Consensus Estimate by 3 cents. However, adjusted EPS fell by a penny on a year-over-year basis
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex Gets Health Canada Approval for Genotyping Assay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 5:35PM CST
Developer and seller of proprietary biological testing technologies, Luminex Corp (LMNX), recently received Health Canada approval for its genotyping assay, xTAG CYP2D6 Kit v3.
ABMD: 60.39 (+0.46), INGN: 33.53 (+2.32), LMNX: 15.45 (+0.02), SURG: 4.44 (-0.02)
Luminex CF Ops up 71%
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:37PM CST
LMNX: 15.45 (+0.02)
